Communiqués Sight Sciences, Inc.

Actions

SGHT

US82657M1053

Equipement, fournitures et distribution médicale

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
8,140 ^USD	+1,69%		-2,51%	+2,65%

19/08	Sight Sciences obtient une extension d'indication de la FDA pour son traitement TearCare contre la sécheresse oculaire	MT
19/08	Sight Sciences annonce une mise à jour de la FDA étendant l'indication du système TearCare à l'amélioration de la fonction des glandes de Meibomius dans la sécheresse oculaire par évaporation	CI

Communiqués

01/09	Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15	AQ
19/08	TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease	AQ
19/08	Sight Sciences : Initial Statement of Beneficial Ownership (Form 3)	PU
06/08	Sight Sciences : Reports Second Quarter 2026 Financial Results	PU
05/08	Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems	AQ
04/08	Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System	AQ
22/07	Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026	AQ
06/05	Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance	AQ
29/04	Sight Sciences to Present at Two Upcoming Investor Conferences	AQ
22/04	Sight Sciences Announces the Release of its Sustainability Report	AQ
21/04	Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026	AQ
01/04	Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
30/03	Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th	AQ
30/03	Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent	AQ
06/03	Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses	AQ
04/03	Sight Sciences : Investor Presentation - March 2026	PU
04/03	Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance	AQ
18/02	Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026	AQ
13/01	Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights	AQ
12/11	Sight Sciences, Inc. - New Peer-Reviewed Publications Highlight Effectiveness of OMNI Surgical System with TruSync Technology in Reducing IOP and Medication Usage	AQ
11/11	New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans	AQ
06/11	Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance	AQ
06/11	Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer	AQ
04/11	Sight Sciences to Present at Two Upcoming Investor Conferences	AQ
23/10/25	Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025	AQ